Business Context and Reporting Period
This Form 6-K filing by Methanex Corporation (Methanex) dated June 27, 2025, discloses the execution of Amendment No. 3 to the Equity Purchase Agreement (EPA) originally dated September 8, 2024. The agreement involves Methanex (the "Parent" and "Buyers") and OCI N.V. (the "Seller" or "Omega") regarding the acquisition of equity interests in specific target companies, including BioMCN. The amendment refines terms related to purchase price allocation, share issuance mechanics, tax responsibilities, and the resolution of specific legal disputes.
Key Financial Metrics
The filing text does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for Methanex Corporation. The document is a legal contract amendment rather than a financial results report.
Material Changes and Contractual Amendments
The amendment introduces several material changes to the original EPA:
- Purchase Price Allocation: Methanex must deliver a schedule allocating consideration between US and NL Purchased Equity Interests within 20 business days of the Final US/NL Adjustment Report. Disputes regarding this allocation will be resolved by an independent Accounting Firm.
- Share Issuance and Legends: Methanex will issue equity consideration shares to Omega at closing. These shares will carry a legend restricting trading for four months and one day after the distribution date, unless permitted by securities legislation.
- EU Allowance (EUA) Rights: Omega retains the right to manage and control legal actions against the Dutch Emission Authority regarding EUAs for BioMCN (Emissions Years 2014–2025) for 24 months post-closing. Any recovery from such actions will be treated per the EPA terms.
- Dispute Resolution (Utility and Demurrage): The parties acknowledge an ongoing dispute regarding overdue utility invoices and a demurrage claim. Methanex has the option to either transfer control of these proceedings to Omega or withdraw from them, with specific financial adjustments to the Final US/NL Adjustment Report depending on the election made.
- Tax Provisions: Detailed amendments clarify the allocation of tax liabilities for "Straddle Periods," the termination of tax sharing agreements, and Omega's indemnification obligations for pre-closing restructuring taxes.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on market outlook. However, it highlights specific risks and contingencies:
- Legal Contingencies: The outcome of the pending appeal and district court proceedings regarding utility invoices and demurrage claims will impact the final transaction price and working capital adjustments.
- Regulatory Risk: The handling of EUAs and potential actions against the Dutch Emission Authority represent a specific regulatory risk area where Omega retains control post-closing.
- Securities Restrictions: The equity consideration shares issued to Omega are subject to trading restrictions and are not registered under U.S. Securities Laws at the time of closing.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing utility invoice and demurrage claim disputes between the parties.
- Confirm the timeline for the "Final US/NL Adjustment Report" and the subsequent purchase price allocation schedule.
- Monitor the 24-month period during which Omega retains control over EUA-related legal actions and any resulting recoveries.
- Review the specific terms of the IT Transition Services Agreement to be executed at closing.
- Assess the implications of the tax indemnification clauses regarding pre-closing restructuring taxes and straddle periods.